Humacyte, Inc. (HUMA)

Nasdaq Biotechnology Diagnostics SIC: 2836
D
Pipeline Grade

Financial Position (from SEC Filings)

$48.9M
Cash & Equivalents
$25.1M
Quarterly Burn Rate
6 mo
Est. Cash Runway
$255M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

No upcoming catalysts detected for this company.

Active Clinical Trials (1)

NCT #TitlePhaseStatusEnrollment
NCT03005418 Humacyte Human Acellular Vessel (HAV) in Patients With Vascular Trauma PHASE3 Active Not Recruiting 72

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for HUMA.

SEC EDGAR Filings

All SEC filings for Humacyte, Inc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.